Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitiglinide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 7/20 | 0.53 |
| ▸ | CPA3 | P15088 | 3/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitiglinide SCHEMBL2864873 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL49085 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL676865 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4457950 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9049521 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4457953 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL6135224 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL305840 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9047711 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9047718 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | claimed |
| EP-3323818-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | claimed |
| EP-2619198-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-07-31 | — | — | EP | claimed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| WO-2012040279-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| EP-1127876-B1 | Process for the preparation of isoindoline | SERVIER LAB (FR) | 2002-11-13 | — | — | EP | claimed |
| US-20010023294-A1 | New process for the preparation of isoindoline | KISSEI PHARMACEUTICAL COMPANY LTD (JP) | 2001-09-20 | — | — | US | claimed |
| EP-0507534-B1 | Succinic acid compounds | KISSEI PHARMACEUTICAL (JP) | 1996-02-28 | — | — | EP | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | disclosed |
| CN-114890933-B | Preparation method of racemic mitiglinide | 恒升德康(南京)医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | disclosed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-1999001430-A1 | METHOD FOR PREPARING A SUBSTITUTED PERHYDROISOINDOLE | ADIR (FR) | 1999-01-14 | — | — | WO | disclosed |
| EP-0507534-B1 | Succinic acid compounds | KISSEI PHARMACEUTICAL (JP) | 1996-02-28 | — | — | EP | disclosed |
| US-5202335-A | Hypoglycemic, antidiabetic agents | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0507534-A1 | Succinic acid compounds | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | CPA1 1870/4885CPA3 2774/4885CPB1 2468/4885 |
| US-20010023294-A1 | New process for the preparation of isoindoline | HPD, GABRB2, NISCH | CPA1 4815/4885CPA3 4601/4885CPB1 2722/4885 |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, DPP4 | CPA1 1865/4885CPA3 2306/4885CPB1 2821/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | CPA1 1758/4885CPA3 2375/4885CPB1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.